12-Month ADAPT Results

One-year data from 82 patients in ADAPT show patients who used Medtronic’s 780G advanced hybrid closed loop continuous glucose monitoring system could control their blood glucose more effectively than patients randomized to treatment with multiple daily injections of insulin and intermittently scanned glucose monitoring.

The initial six-month results, published in Lancet Diabetes & Endocrinology showed 780G users improved their “time in range” by about 28% with a 1.4% reduction in HbA1C compared to the control subjects. (Also see "Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G" - Medtech Insight, 8 September, 2022.)

After six months, the control patients in the trial “crossed over” and started using the 780G system. At one year, the significant benefits of the 780G system shown in the first six months were sustained in the original 780G group as well as the crossover group.

Talking ATTD, 780G, Rumors And Missteps With Medtronic’s Diabetes Leaders

More from Clinical Trials

More from R&D